Literature DB >> 20502314

Effect of hormonal contraceptive use on HIV progression in female HIV seroconverters in Rakai, Uganda.

Chelsea B Polis1, Maria J Wawer, Noah Kiwanuka, Oliver Laeyendecker, Joseph Kagaayi, Tom Lutalo, Fred Nalugoda, Godfrey Kigozi, David Serwadda, Ronald H Gray.   

Abstract

OBJECTIVE: To assess the association between hormonal contraceptive use and HIV progression.
DESIGN: A retrospective analysis of 625 female HIV seroconverters from a Ugandan cohort study.
METHODS: Multivariate Cox regression analyses incorporating time-varying hormonal contraceptive exposure were used to estimate the adjusted hazard ratios of death, and a composite outcome of AIDS or death, associated with hormonal contraceptive use. Sensitivity analyses included lagging hormonal contraceptive exposure, varying comparison groups, and separately assessing effects of oral and injectable contraceptives.
RESULTS: A total of 27.5% of women reported ever using hormonal contraception. Of 625 women, 104 (16.6%) died and 291 (46.6%) progressed to AIDS or death during observation. Time-varying hormonal contraceptive use was not associated with an increased hazard of death as compared with nonuse of hormonal contraception (adjusted hazard ratio 0.76, 95% confidence interval 0.41-1.39, P = 0.37), and was associated with a significantly reduced hazard of progression to AIDS or death (adjusted hazard ratio 0.70, 95% confidence interval 0.50-0.97, P = 0.03). None of the sensitivity analyses suggested an adverse effect of hormonal contraception on HIV progression.
CONCLUSION: Hormonal contraceptive use was not associated with faster progression to death, and was associated with a reduced hazard of progression to the composite outcome of AIDS or death.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20502314      PMCID: PMC2939866          DOI: 10.1097/QAD.0b013e32833b3282

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  27 in total

1.  Are HIV-infected women who breastfeed at increased risk of mortality?

Authors:  A Coutsoudis; H Coovadia; K Pillay; L Kuhn
Journal:  AIDS       Date:  2001-03-30       Impact factor: 4.177

2.  Trends in HIV-1 prevalence may not reflect trends in incidence in mature epidemics: data from the Rakai population-based cohort, Uganda.

Authors:  M J Wawer; D Serwadda; R H Gray; N K Sewankambo; C Li; F Nalugoda; T Lutalo; J K Konde-Lule
Journal:  AIDS       Date:  1997-07       Impact factor: 4.177

3.  Impact of pregnancy on maternal AIDS.

Authors:  R M Kumar; S A Uduman; A K Khurrana
Journal:  J Reprod Med       Date:  1997-07       Impact factor: 0.142

4.  A randomized, community trial of intensive sexually transmitted disease control for AIDS prevention, Rakai, Uganda.

Authors:  M J Wawer; R H Gray; N K Sewankambo; D Serwadda; L Paxton; S Berkley; D McNairn; F Wabwire-Mangen; C Li; F Nalugoda; N Kiwanuka; T Lutalo; R Brookmeyer; R Kelly; T C Quinn
Journal:  AIDS       Date:  1998-07-09       Impact factor: 4.177

5.  Effect of breastfeeding on mortality among HIV-1 infected women: a randomised trial.

Authors:  R Nduati; B A Richardson; G John; D Mbori-Ngacha; A Mwatha; J Ndinya-Achola; J Bwayo; F E Onyango; J Kreiss
Journal:  Lancet       Date:  2001-05-26       Impact factor: 79.321

6.  Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group.

Authors:  M J Wawer; N K Sewankambo; D Serwadda; T C Quinn; L A Paxton; N Kiwanuka; F Wabwire-Mangen; C Li; T Lutalo; F Nalugoda; C A Gaydos; L H Moulton; M O Meehan; S Ahmed; R H Gray
Journal:  Lancet       Date:  1999-02-13       Impact factor: 79.321

7.  Repertoire of chemokine receptor expression in the female genital tract: implications for human immunodeficiency virus transmission.

Authors:  B K Patterson; A Landay; J Andersson; C Brown; H Behbahani; D Jiyamapa; Z Burki; D Stanislawski; M A Czerniewski; P Garcia
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

8.  Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in women.

Authors:  Ludo Lavreys; Jared M Baeten; Joan K Kreiss; Barbra A Richardson; Bhavna H Chohan; Wisal Hassan; Dana D Panteleeff; Kishorchandra Mandaliya; Jeckoniah O Ndinya-Achola; Julie Overbaugh
Journal:  J Infect Dis       Date:  2004-01-09       Impact factor: 5.226

9.  Identification of modifiable factors that affect the genetic diversity of the transmitted HIV-1 population.

Authors:  Manish Sagar; Ludo Lavreys; Jared M Baeten; Barbra A Richardson; Kishorchandra Mandaliya; Jeckoniah O Ndinya-Achola; Joan K Kreiss; Julie Overbaugh
Journal:  AIDS       Date:  2004-03-05       Impact factor: 4.177

Review 10.  Hormonal regulation of uterine macrophages.

Authors:  J S Hunt; L Miller; J S Platt
Journal:  Dev Immunol       Date:  1998
View more
  17 in total

1.  Hormonal contraceptive use and HIV disease progression among women in Uganda and Zimbabwe.

Authors:  Charles S Morrison; Pai-Lien Chen; Immaculate Nankya; Anne Rinaldi; Barbara Van Der Pol; Yun-Rong Ma; Tsungai Chipato; Roy Mugerwa; Megan Dunbar; Eric Arts; Robert A Salata
Journal:  J Acquir Immune Defic Syndr       Date:  2011-06-01       Impact factor: 3.731

2.  Hormonal Contraception and Risk of Psychiatric and Other Noncommunicable Diseases in HIV-Infected Women.

Authors:  Jessica L Castilho; Cathy A Jenkins; Bryan E Shepherd; Sally S Bebawy; Megan Turner; Timothy R Sterling; Vlada V Melekhin
Journal:  J Womens Health (Larchmt)       Date:  2015-03-09       Impact factor: 2.681

Review 3.  Hormonal contraception and HIV-1 transmission.

Authors:  Catherine A Blish; Jared M Baeten
Journal:  Am J Reprod Immunol       Date:  2010-11-19       Impact factor: 3.886

4.  Associations of hormonal contraceptive use with measures of HIV disease progression and antiretroviral therapy effectiveness.

Authors:  Maura K Whiteman; Gary Jeng; Anna Samarina; Natalia Akatova; Margarita Martirosyan; Dmitry M Kissin; Kathryn M Curtis; Polly A Marchbanks; Susan D Hillis; Michele G Mandel; Denise J Jamieson
Journal:  Contraception       Date:  2015-07-18       Impact factor: 3.375

5.  Effect of hormonal contraceptive use before HIV seroconversion on viral load setpoint among women in Rakai, Uganda.

Authors:  Chelsea B Polis; Ronald H Gray; J B Bwanika; Godfrey Kigozi; Noah Kiwanuka; Fred Nalugoda; Joseph Kagaayi; Tom Lutalo; David Serwadda; Maria J Wawer
Journal:  J Acquir Immune Defic Syndr       Date:  2011-02-01       Impact factor: 3.731

6.  Characterization of a Hormone-Responsive Organotypic Human Vaginal Tissue Model: Morphologic and Immunologic Effects.

Authors:  Seyoum Ayehunie; Ayesha Islam; Chris Cannon; Timothy Landry; Jeffrey Pudney; Mitchell Klausner; Deborah J Anderson
Journal:  Reprod Sci       Date:  2015-02-11       Impact factor: 3.060

Review 7.  Drug-Drug Interactions, Effectiveness, and Safety of Hormonal Contraceptives in Women Living with HIV.

Authors:  Kimberly K Scarsi; Kristin M Darin; Catherine A Chappell; Stephanie M Nitz; Mohammed Lamorde
Journal:  Drug Saf       Date:  2016-11       Impact factor: 5.606

8.  Hormonal contraceptive use and risk of HIV-1 disease progression.

Authors:  Renee Heffron; Nelly Mugo; Kenneth Ngure; Connie Celum; Deborah Donnell; Edwin Were; Helen Rees; James Kiarie; Jared M Baeten
Journal:  AIDS       Date:  2013-01-14       Impact factor: 4.177

9.  Hormonal contraceptive use and discontinuation among HIV-infected women in Uganda and Zimbabwe.

Authors:  Angela Bengtson; Cynthia Kwok; Robert A Salata; Josaphat Byamugisha; Tsungai Chipato; Sandra Rwambuya; Precious Moyo; Charles S Morrison
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-01       Impact factor: 3.731

10.  Women with pregnancies had lower adherence to 1% tenofovir vaginal gel as HIV preexposure prophylaxis in CAPRISA 004, a phase IIB randomized-controlled trial.

Authors:  Lynn T Matthews; Sengeziwe Sibeko; Leila E Mansoor; Nonhlanhla Yende-Zuma; David R Bangsberg; Quarraisha Abdool Karim
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.